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What are the novel findings of this work?
This is the first systematic review assessing the incremental
diagnostic yield of prenatal exome sequencing over
chromosomal microarray analysis or karyotyping in
prenatally diagnosed non-immune hydrops fetalis. An
apparent incremental yield of exome sequencing was
demonstrated.
What are the clinical implications of this work?
Prenatal exome sequencing should be considered in
prenatally diagnosed non-immune hydrops fetalis that
is unexplained by standard genetic testing, in both
isolated cases and those associated with an additional
fetal structural anomaly.
ABSTRACT
Objective To determine the incremental yield of exome
sequencing (ES) over chromosomal microarray ana-
lysis (CMA) or karyotyping in prenatally diagnosed
non-immune hydrops fetalis (NIHF).
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Methods A prospective cohort study (comprising an
extended group of the Prenatal Assessment of Genomes
and Exomes (PAGE) study) was performed which
included 28 cases of prenatally diagnosed NIHF undergo-
ing trio ES following negative CMA or karyotyping. These
cases were combined with data from a systematic review
of the literature. MEDLINE, EMBASE, CINAHL and
ClinicalTrials.gov databases were searched electronically
(January 2000 to October 2020) for studies reporting on
the incremental yield of ES over CMA or karyotyping in
fetuses with prenatally detected NIHF. Inclusion criteria
for the systematic review were: (i) at least two cases of
NIHF undergoing sequencing; (ii) testing initiated based
on prenatal ultrasound-based phenotype; and (iii) negative
CMA or karyotyping result. The incremental diagnos-
tic yield of ES was assessed in: (i) all cases of NIHF;
(ii) isolated NIHF; (iii) NIHF associated with an addi-
tional fetal structural anomaly; and (iv) NIHF according
to severity (i.e. two vs three or more cavities affected).
Results In the extended PAGE study cohort, the addi-
tional diagnostic yield of ES over CMA or karyotyping
was 25.0% (7/28) in all NIHF cases, 21.4% (3/14) in
those with isolated NIHF and 28.6% (4/14) in those with
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non-isolated NIHF. In the meta-analysis, the pooled incre-
mental yield based on 21 studies (306 cases) was 29%
(95% CI, 24–34%; P < 0.00001; I2 = 0%) in all NIHF,
21% (95% CI, 13–30%; P < 0.00001; I2 = 0%) in iso-
lated NIHF and 39% (95% CI, 30–49%; P < 0.00001;
I2 = 1%) in NIHF associated with an additional fetal
structural anomaly. In the latter group, congenital limb
contractures were the most prevalent additional structural
anomaly associated with a causative pathogenic variant,
occurring in 17.3% (19/110) of cases. The incremental
yield did not differ significantly according to hydrops
severity. The most common genetic disorders identified
were RASopathies, occurring in 30.3% (27/89) of cases
with a causative pathogenic variant, most frequently due
to a PTPN11 variant (44.4%; 12/27). The predominant
inheritance pattern in causative pathogenic variants was
autosomal dominant in monoallelic disease genes (57.3%;
51/89), with most being de novo (86.3%; 44/51).
Conclusions Use of prenatal next-generation sequencing
in both isolated and non-isolated NIHF should be
considered in the development of clinical pathways. Given
the wide range of potential syndromic diagnoses and
heterogeneity in the prenatal phenotype of NIHF, exome
or whole-genome sequencing may prove to be a more
appropriate testing approach than a targeted gene panel
testing strategy. © 2021 The Authors. Ultrasound in
Obstetrics & Gynecology published by John Wiley &
Sons Ltd on behalf of International Society of Ultrasound
in Obstetrics and Gynecology.
INTRODUCTION
Non-immune hydrops fetalis (NIHF) is defined tradition-
ally as fluid accumulation in two or more fetal body
cavities in cases not secondary to maternal red cell
alloimmunization1. It affects up to 1 in 1700 pregnan-
cies, with associated high risks of perinatal morbidity
and mortality2. Excluding cases due to infection, fetal
structural anomaly (FSA) or complications of twin preg-
nancy, aneuploidy may explain one-quarter of cases, with
chromosomal microarray analysis (CMA) demonstrat-
ing copy-number variants (CNVs) in a further 6–14%
of cases3,4. Despite this, the definitive diagnostic yield
of CMA over standard G-banding karyotyping is mod-
erate and, following exclusion of the aforementioned
causes, up to 50% of cases of NIHF remain unexplained,
with a significant proportion thought to be secondary to
single-gene variants5. Over 170 genes have been identi-
fied as being associated with NIHF and, until the recent
emergence of next-generation sequencing (NGS), testing
for such conditions has relied on targeted gene testing
and enzyme assays3,6. Single-gene causes of NIHF are
associated with significant risks of perinatal death or neu-
rodevelopmental sequelae2. Establishing the diagnostic
etiology of NIHF prenatally is a vital step in facilitating
informed decision-making for both parents and clinicians
when considering options such as termination of preg-
nancy, planning neonatal care and addressing recurrence
risks2. The latter risk could theoretically be mitigated by
using novel technologies, such as preimplantation genetic
testing7. While individual cohort studies have assessed the
diagnostic yield of exome sequencing (ES) over quantita-
tive fluorescence polymerase chain reaction (QF-PCR) and
CMA or karyotyping in NIHF, they are heterogeneous in
relation to the populations assessed and the genetic plat-
forms used3. Given this heterogeneity, there is a need to
integrate existing data on single-gene disorders underlying
NIHF. Hence, the aims of this study were to evaluate the
incremental diagnostic yield of prenatal ES over CMA or
karyotyping in prenatally diagnosed NIHF for: (i) all cases
of NIHF; (ii) isolated NIHF; (iii) NIHF associated with an
additional FSA; and (iv) NIHF according to severity (i.e.
two cavities vs three or more cavities affected).
METHODS
Extended PAGE study cohort
The Fetal hydrops and the Incremental yield of
Next-generation sequencing over standard prenatal
Diagnostic testing (FIND) study included prospectively
identified cases of prenatally confirmed NIHF from
an extended cohort of the Prenatal Assessment of
Genomes and Exomes (PAGE) study8. For the purposes
of this study, we defined NIHF as pathological fluid
accumulation in at least two fetal cavities confirmed
prenatally on ultrasound, excluding cases with aneu-
ploidy, congenital infection, alloimmunization and/or
twin–twin transfusion syndrome1,2. The final extended
PAGE cohort comprised 850 fetuses (including 596 of the
published cohort) with fetal–parental trio ES performed
when an ultrasound-confirmed FSA was detected8. These
cases were recruited between October 2014 and May
2018 across 34 fetal medicine centers in England and
Scotland, with ES performed centrally at the Wellcome
Trust Sanger Institute, Hinxton, UK8. PAGE eligibility
criteria included: (i) prenatal detection of a FSA after
11 weeks’ gestation; (ii) availability of proband and
parental DNA; and (iii) negative CMA or karyotyping
result. The PAGE study methodology has been published
previously and utilized a standard ES approach with
variant interpretation based on a targeted virtual gene
panel for developmental disorders encompassing 1628
genes8,9. Phenotypes of all cases were classified using
Human Phenotype Ontology (HPO) terms10, and those
defined as hydrops fetalis (HP:0001789) were selected
and analyzed further to determine if the criteria for
NIHF for the purposes of the FIND study were met.
Cases were classified further as isolated or associated
with an additional FSA using the HPO approach to
coding additional anomalies. The fetal phenotype was
described by fetal medicine specialists/sonographers
and documented principally on ViewPoint® version
5.6.16 (GE Healthcare, Zipf, Austria). Variants were
classified in accordance with the American College of
Medical Genetics and Genomics (ACMG) guidelines11,
as agreed by a clinical review panel, and incidental
findings (IFs) were not reported. Pathogenic and likely
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pathogenic variants explaining the fetal phenotype were
confirmed using Sanger sequencing, and the results were
returned to the parents after the end of the pregnancy.
Ethical approval was obtained from the research ethics
committees at West Midlands – South Birmingham (ref:
13/WM/1219) and Harrow (ref: 01/0095). Local research
and development offices subsequently approved the study
at each participating organization.
Systematic review and meta-analysis
Information sources
This review was performed in a standardized manner in
line with recommended methods for systematic reviews
and the preferred reporting items for systematic reviews
and meta-analyses (PRISMA)12 and meta-analysis of
observational studies in epidemiology (MOOSE)13
guidance and was registered prospectively (PROSPERO
No. CRD42020221427). The following databases were
searched electronically for relevant citations, from
January 2000 (ES technology was not available prior
to this time) until October 2020: MEDLINE, EMBASE,
CINAHL and ClinicalTrials.gov. The search strategy
consisted of relevant medical subject headings (MeSH)
terms, keywords and word variants for ‘exome sequenc-
ing’, ‘fetus’ and ‘abnormality’, used with alternative
terms encompassing ‘genome sequencing’, ‘exome’,
‘fetal’, ‘prenatal’, ‘antenatal’, ‘defect’ and ‘anomaly’.
Bibliographies of relevant articles were searched manually
and experts in prenatal genomics were contacted to
identify further relevant studies. The search strategy is
available from the corresponding author on request.
Study selection
The inclusion criteria for study selection were any
prospective or retrospective cohort study or case series
which: (i) included two or more cases of NIHF
undergoing ES; (ii) initiated testing based on prenatal
ultrasound-based phenotype; (iii) included cases with a
negative CMA or karyotyping result; and (iv) included
cases with known genetic testing result. Cases in which
ES was initiated postnatally were included if testing
was based on the prenatal phenotype. Cases in which
sequential Sanger sequencing was utilized were also
included. When studies were not specific to NIHF
exclusively, data regarding NIHF cases were extracted
from the paper or were requested from the corresponding
author. All study abstracts were screened by two reviewers
(F.M. and M.D.K.) and the full manuscripts were reviewed
subsequently when further information was required.
Data extraction and quality assessment
Both reviewers extracted independently data on study
characteristics and outcome using a proforma. Data
extracted from studies, when obtainable, included:
ultrasound phenotype, sequencing approach, reported
variants, source of fetal DNA, turnaround time, fetal
outcome, maternal age and gestational age at testing.
Quality assessment was performed using modified
standards for reporting of diagnostic accuracy studies
(STARD) criteria14. The criteria deemed most important
to optimize accuracy were: (i) trio analysis; (ii) use of
ACMG criteria for variant interpretation; (iii) Sanger
sequencing validation; and (iv) description of the prenatal
phenotype.
Statistical analysis
Descriptive tables were produced detailing study char-
acteristics and outcomes. The incremental diagnostic
yield for causative Class-IV and Class-V variants, or risk
difference, with 95% CI, of ES over CMA or karyotyping
was calculated for each study and as a pooled value for: (i)
all NIHF; (ii) isolated NIHF; (iii) NIHF associated with an
additional FSA; and (iv) NIHF according to severity (i.e.
two vs three or more cavities affected). When reported,
pooled values for variants of uncertain significance
(VOUS) and IFs were also determined. Risk differences
from each study were pooled using a random-effects
model throughout to estimate incremental yield using a
previously published method which facilitates calculation
with adjustment for zero values from negative CMA
or karyotyping9,15. Results were displayed in forest
plots with corresponding 95% CI. Heterogeneity was
assessed graphically using forest plots and statistically
using the Higgins I2 statistic. Publication bias was
assessed graphically using funnel plots. Statistical analysis
was performed using RevMan version 5.3.4 (Review
Manager; The Cochrane Collaboration, Copenhagen,
Denmark) statistical software.
RESULTS
Extended PAGE study cohort
Of the 850 cases with a FSA detected prenatally on
ultrasound that underwent ES in the extended PAGE
cohort, 28 (3.3%) met the definition for NIHF. Of
these, 50.0% (n = 14) were apparently isolated and
50.0% (n = 14) were associated with an additional
FSA. In the majority of cases (96.4%; 27/28), the
initial genetic test was CMA, while the remainder
had karyotyping, and proband DNA most frequently
originated from cultured amniocytes (50.0%; n = 14).
The additional diagnostic yield of ES was 25.0% (7/28)
in all NIHF cases, 21.4% (3/14) in isolated NIHF cases
and 28.6% (4/14) in NIHF cases associated with an
additional FSA. When an additional anomaly associated
with a causative pathogenic variant was present, the
most common additional anomaly was congenital limb
contractures due to arthrogryposis multiplex congenita
(HP0002804) (75%; 3/4). In cases with an associated
anomaly in which no causative pathogenic variant was
obtained, the most common additional anomalies were
cardiac, genitourinary or thoracic in nature (50.0%
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(5/10) for each). One case of Noonan syndrome was
not detected initially as pathogenic as it was filtered out
of the bioinformatic pipeline due to inheritance from an
apparently unaffected parent. Subsequently, the pipeline
was adjusted so that such variants were not filtered out
even if they were inherited. The incidence of VOUS was
7.1% (2/28). Causative pathogenic variants (Classes IV
and V) and VOUS are described in Tables S1 and S2,
respectively.
Systematic review and meta-analysis
For nine studies that were suitable for inclusion but data
were incomplete, the corresponding author was contacted
to request further data regarding fetal phenotype, of
whom two responded and provided full datasets16,17.
For the study of Petrovski et al.16, based in Columbia
University Medical Centre, New York, USA, the authors
provided an extended dataset. In total, in addition to the
extended PAGE study cohort, a further 20 studies met
the inclusion criteria (Figure 1)2,16–34. Table 1 shows the
characteristics of the included studies and Figure 2 shows
the overall quality assessment.
The 21 included studies encompassed a total of 306
NIHF cases. When stated (n = 218), there were 109
(50.0%) cases of apparently isolated NIHF (on detailed
prenatal ultrasound) and 109 (50.0%) cases associated
with an additional FSA. Mean maternal age and
gestational age at testing were 30.9 ± 3.5 years and 21.9
± 5.4 weeks, respectively. Fetal DNA was obtained via
amniocentesis in the majority of cases (50.6%; 121/239).
The initial test prior to ES was CMA in 84.0% (257/306)
of cases and G-banding karyotyping in the remainder.
When documented (eight studies), the median turnaround
time for ES was 40 (range, 7–140) days. Pregnancy
outcome was available for 83.7% (256/306) of cases (ter-
mination of pregnancy (35.2%; 90/256), in-utero demise
(34.4%; 88/256), neonatal survival (22.3%; 57/256) and
neonatal death (8.2%; 21/256)). When reported (60.8%;
186/306), the pooled incremental yield for VOUS and IFs
was 19% (95% CI, 6–22%; P = 0.003; I2 = 62%) and
4% (95% CI, −1 to 9%; P = 0.09; I2 = 0%), respectively.
All documented pathogenic variants and VOUS are
outlined in Tables S1 and S2, respectively.
The pooled incremental yield of ES in all NIHF cases,
those with isolated NIHF and those with NIHF associated
with an additional FSA is demonstrated in forest plots,
with respective values of 29% (95% CI, 24–34%;
P < 0.00001; I2 = 0% (Figure 3)), 21% (95% CI,
13–30%; P < 0.00001; I2 = 0% (Figure 4)) and 39%
(95% CI, 30–49%; P < 0.00001; I2 = 1% (Figure 5)).
The corresponding funnel plots are displayed in Figure S1.
In cases with an additional FSA, the most common addi-
tional anomalies associated with a causative pathogenic
variant were those affecting the upper and/or lower limbs
due to congenital contractures (HP:0002803) (17.3%;
Total citations identified (n = 604):
 • MEDLINE/CINAHL (n = 162)
 • EMBASE (n = 407)
 • ClinicalTrials.gov (n = 2)
 • Experts (n = 2)
 • Study citations (n = 30)
 • Extended PAGE cohort (n = 1)
Studies retrieved for detailed evaluation
(n = 88)
Excluded (n = 516):
 • Duplicates removed (n = 136)
 • Removed after screening abstract (n = 380) 
Excluded (n = 67):
 • Fewer than two cases (n = 16)
 • CMA/karyotyping not performed before ES
 (n = 10)
 • Cases with fluid in  two or more body cavities
 not included (n = 20)
 • Testing based on postnatal phenotype (n = 14)
 • Inadequate data to determine inclusion (n = 7)*
Studies included in systematic review
(n = 21; 306 cases)
Figure 1 Flowchart summarizing inclusion in the systematic review of studies on the incremental yield of exome sequencing (ES) over
chromosomal microarray analysis (CMA) or karyotyping in fetuses with prenatally detected non-immune hydrops fetalis. *Corresponding
author was contacted to request additional information but did not respond. PAGE, Prenatal Assessment of Genomes and Exomes study.
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19/110). When the NIHF phenotype was described
(n = 156), the incremental yield for causative pathogenic
variants did not differ significantly according to the
severity of hydrops (two cavities affected (34%; 95% CI,
23–45%; P < 0.00001; I2 = 0%) vs three or more cavities
affected (30%; 95% CI, 19–40%; P < 0.00001; I2 = 0%);
P = 0.26) (Figure S2). When a causative pathogenic vari-
ant was documented (n = 89) (Table S1), the most
common genetic disorders were: (i) RASopathies (30.3%;
27/89), primarily due to PTPN11 variants (44.4%;
12/27); (ii) musculoskeletal disorders (14.6%; 13/89),
primarily due to RYR1 variants (38.5%; 5/13); and (iii)
inborn errors of metabolism (12.4%; 11/89), primarily
due to GUSB variants (45.5%; 5/11). The predominant
inheritance pattern of causative pathogenic variants was
autosomal dominant in monoallelic disease genes (57.3%;
51/89), with most being de novo (86.3%; 44/51). When
the type of ES performed was stated (20 studies; Table 1),
the overall incremental yield did not differ significantly
according to whether a panel or whole-exome approach
was used (26% (95% CI, 16–36%; I2 = 0%) and 27%
(95% CI, 19–36%; I2 = 25%), respectively).
DISCUSSION
The findings of this systematic review demonstrate a
substantial incremental yield of 29% of ES over CMA
or karyotyping in cases with prenatally diagnosed NIHF.
This yield was higher among cases with an additional
FSA, but severity of NIHF did not demonstrate a
significant effect on the incremental yield. The majority of
causative pathogenic variants were de novo in autosomal
dominant disease genes, predominantly in those causative
of RASopathies.
Table 1 Characteristics of included studies reporting on the incremental yield of exome sequencing over chromosomal microarray analysis
or karyotyping in fetuses with prenatally detected non-immune hydrops fetalis (NIHF)
Number of NIHF cases
Study Next-generation sequencing approach All Isolated
With additional
FSA
Becher (2020)26 WES, trio, 103× coverage, Roche SeqCap EZ MedExome Plus
capture + Illumina NextSeq 500
4 4 0
Boissel (2018)18 WES, trio, 110× coverage, Agilent capture + Illumina HiSeq 2000
or 2500
2 0 2
Corsten-Janssen (2020)32 WES, trio, 20× coverage, Agilent capture + Illumina NextSeq500 6 2 4
Croonen (2013)33* Clinical exome, Noonan panel, Illustra amplification, sequencer
not stated
15 N/S N/S
Deden (2020)27 WES, trio, 200–300× coverage, Agilent capture + Illumina
NextSeq500
4 1 3
Deng (2020)19 WES, trio, 120× coverage, Agilent capture + Illumina HiSeq X Ten
or Novaseq 6000
21 16 5
Greenbaum (2019)28 WES, trio, 100× coverage, capture kit unknown + Illumina
sequencing
3 2 1
Jelin (2020)20 WES, trio, depth of coverage < 10 removed, Agilent capture +
Illumina HiSeq 2500
5 3 2
Lord (2020)8† WES, trio, 1628 genes, Agilent capture + Illumina HiSeq 2500,
98.3% of bait regions covered at minimum depth of 5×
28 14 14
Mone (2020)34 WES, trio, 1628 genes, Agilent capture + Illumina HiSeq 2500,
98.3% of bait regions covered at minimum depth of 5×
6 3 3
Normand (2018)21 WES, trio, 150× coverage, Roche NimbleGen capture, Illumina
Genome Analyzer IIx platform/HiSeq 2000
10 N/S N/S
Petrovski (2019)16 WES, trio, Nimblegen SeqCap EZ capture + Illumina Hiseq 2500,
average read coverage 89.3 reads, bioinformatic signatures
23 14 9
Sparks (2019)29* WES (n = 1), clinical exome (n = 7), other details not specified 8 N/S N/S
Sparks (2020)2* WES, trio, Illumina HiSeq 2500 or Illumina NovaSeq 6000 78 32 46
Stals (2018)23 WES, parents only, 80× coverage, Agilent capture + Illumina HiSeq
2500 or NextSeq500, included only heterozygous rare
(MAF < 0.001) variants in same gene in both parents
4 0 4
Vora (2017)22* Clinical exome and WES, trio, Illumina HiSeq 2500 2 2 0
Westerfield (2015)30 WES, trio, 130× coverage, Roche NimbleGen capture + Illumina
Genome Analyzer IIx or HiSeq 2000
2 0 2
Westphal (2019)24 WES, trio, 20 000 genes, 150× coverage 2 0 2
Yang (2012)31* Clinical exome, lymphedema panel, Oligo 6.1 PCR
amplification + ABI, PRISM 3000 DNA sequencer
27 N/S N/S
Yates (2017)25 WES, trio, 140× coverage, Agilent capture + Illumina HiSeq 2000
or 2500
28 N/S N/S
Zhou (2020)17* WES, trio in recurrent NIHF, Agilent capture + Illumina
HiSeq X Ten
28 16 12
Only first author of each study is given. *Coverage not stated. †Including cases identified in the current study. FSA, fetal structural anomaly;
MAF, minor allele freuency; N/S, not stated; PCR, polymerase chain reaction; WES, whole-exome sequencing.
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Clinical patient background described




Description of NGS approach
Eligibility criteria described
Prospective study
Number of patients > 5
Source of patients described
Hydrops-specific study






















Number of studies 21
Figure 2 Quality assessment of 21 studies included in systematic review, using modified standards for reporting of diagnostic accuracy
studies (STARD) criteria. ACMG, American College of Medical Genetics and Genomics; NGS, next-generation sequencing; TAT,






















































































































































306 306 100.0% 0.29 (0.24, 0.34)Total (95% CI)
Total events
Test for overall effect: Z = 10.98 (P < 0.00001)
Heterogeneity: tau2 = 0.00; chi2  =  16.52, df = 20 (P = 0.68); I2 = 0%
–0.5
Favors CMA/karyotyping Favors ES
0 0.5 1–1
CMA/karyotypingES
Events Total Events Total Weight M–H, random, 95% CI M–H, random, 95% CI
Incremental yield Incremental yield
Figure 3 Forest plot showing incremental yield of exome sequencing (ES) over chromosomal microarray analysis (CMA) or karyotyping in
all fetuses with prenatally detected non-immune hydrops fetalis. Only first author of each study is given. M–H, Mantel–Haenszel.
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109 109 100.0% 0.21 (0.13, 0.30)Total (95% CI)
Total events
Test for overall effect: Z = 5.15 (P < 0.00001)
Heterogeneity: tau2 = 0.00; chi2 = 4.75, df = 11 (P = 0.94); I2 = 0% –0.5
Favors CMA/karyotyping Favors ES
0 0.5 1–1
CMA/karyotypingES
Events Total Events Total Weight M–H, random, 95% CI M–H, random, 95% CI
Incremental yield Incremental yield
Figure 4 Forest plot showing incremental yield of exome sequencing (ES) over chromosomal microarray analysis (CMA) or karyotyping in





































































































109 109 100.0% 0.39 (0.30, 0.49)Total (95% CI)
Total events
Test for overall effect: Z = 8.23 (P < 0.00001)
Heterogeneity: tau2 = 0.00; chi2 = 13.13, df = 13 (P = 0.44); I2 = 1% –0.5
Favors CMA/karyotyping Favors ES
0 0.5 1–1
CMA/karyotypingES
Events Total Events Total Weight M–H, random, 95% CI M–H, random, 95% CI
Incremental yield Incremental yield
Figure 5 Forest plot showing incremental yield of exome sequencing (ES) over chromosomal microarray analysis (CMA) or karyotyping in
fetuses with prenatally detected non-immune hydrops fetalis with an additional fetal structural anomaly. Only first author of each study is
given. M–H, Mantel–Haenszel.
The findings of the extended PAGE cohort and the
systematic review were broadly concordant, but with a
lower incremental yield of ES in the cohort study, which
may be explained by the smaller number of cases as
well as the unselected approach to case selection. The
high incidence of RASopathies and of de-novo variants
in autosomal dominant disease genes is expected and not
mutually exclusive2. The incremental yield of ES was
higher in NIHF cases in which an additional FSA was
present, particularly in cases of congenital arthrogryposis,
which is intuitive given that contractures are a common
musculoskeletal phenotype known to have a higher
diagnostic yield on sequencing35. In contrast, isolated
NIHF was seen commonly within the RASopathies
(40.7%; 11/27). This is in keeping with the variable
phenotype reported in RASopathies and supports the
use of prenatal ES in cases of isolated NIHF36. There
is phenotypic variability in cases with a pathogenic
variant in other types of genetic disease in addition to
in those with a known RASopathy pathogenic variant.
© 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2021; 58: 509–518.
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This supports the use of ES or whole-genome sequencing
(WGS), rather than a targeted or stepwise approach,
in the investigation of NIHF37. The role of QF-PCR
or conventional karyotyping in NIHF should always
be respected, given the high incidence of aneuploidy38.
However, given the limited additional yield of CMA
over karyotyping, and considering the ability of WGS
to detect both structural variants and aneuploidy, it
may be reasonable in the future to consider WGS as
the second-line test after QF-PCR5. The list of novel
causative genes in NIHF is constantly expanding and,
over time, the yield of prenatal NGS will likely improve
as more genes are discovered and our understanding of
the prenatal phenotype develops2,37. This is supported by
the high number of Class-III variants (VOUS) identified
within candidate genes in this systematic review and
highlighted by the largest included series2. Reanalysis and
potential reclassification of VOUS is currently underway
for the PAGE cohort, which may increase the diagnostic
yield.
Due to the relatively high yield of ES evident in
isolated NIHF in this study (and in individual papers
in the literature), it was decided to add NIHF (from
March 2021) as an indication for inclusion in the R21
pathway of the National Health Service (NHS) England
National Genomic Test Directory for Rare and Inherited
Disease36,39. The R21 pathway is a nationally (England
presently) commissioned rapid prenatal ES service for
fetuses with multiple, multisystemic, major and selected
isolated FSAs, performed by two genomic laboratory
hubs, in line with a set protocol40. Furthermore, the
Fetal Oedema and Lymphatic Disorder (FOLD) study is
ongoing in the UK41.
The selection criteria for this study were based on the
routine definition of NIHF1. It has been proposed that
this definition should be expanded to include pathological
fluid accumulation in one or more fetal body cavity,
inclusive of increased (> 3.5 mm) nuchal translucency
thickness (NT) or cystic hygroma2. This is being explored
further, but appears to be a reasonable argument given
the large variability in NIHF phenotypes as well as their
complex evolution, and sometimes resolution, seen in
causative syndromes such as RASopathies. This notion is
also supported by our finding that the mere presence of
NIHF, as opposed to its severity, influences the diagnostic
yield of ES. Hydropic phenotypes can change during
pregnancy and findings that may be evident in the first
trimester may regress by the third trimester, hence pleural
effusion or cystic hygroma in the first trimester may be
the only opportunity to detect an anomaly and offer
testing. There is a need for studies documenting the
evolution of the different phenotypes of NIHF and the
respective diagnostic yields of NGS. Despite this, prenatal
ES in cases of isolated elevated NT appears to offer a
modest increase in diagnostic yield over CMA2,42–44,
of around 5–7%. The severity of increased (≥ 5 mm)
NT, its persistence and its association with additional
anomalies also appear to influence the diagnostic yield of
NGS2,37,44.
The strengths of this systematic review lie in its
novelty with regard to concept, the robust methodology
utilized, as well as collaboration between experts of some
of the largest contemporary series in this area2,8,16,17.
Despite the relatively small number of cases (n = 306), the
present systematic review represents the largest review of
prenatally diagnosed NIHF cases, and heterogeneity did
not appear to be affected. None of the included studies
used a WGS approach, and therefore the difference in yield
between WGS and ES could not be assessed. The lack of
studies utilizing WGS is likely to change in the coming
years and it will likely prove to be more beneficial than ES
due to its all-in-one ability to detect most chromosomal
and genetic differences7,39.
In conclusion, the use of prenatal NGS in both isolated
NIHF and NIHF associated with an additional FSA should
be considered in the development of clinical pathways.
Given the vast syndromic categories and heterogeneity
in the prenatal phenotype of NIHF, a whole-exome or
WGS approach in combination with accurate prenatal
phenotyping is likely to be a more appropriate tool
than a targeted or stepwise single-gene testing strategy
in achieving an optimum diagnostic yield. The existing
definition of NIHF appears to be appropriate for assessing
the diagnostic yield of ES, although further studies
assessing expansion of this definition are required to
support this.
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CJ, Haendel MA, Robinson PN. The Human Phenotype Ontology in 2021. Nucleic
Acids Res 2021; 49: D1207–1217.
11. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M,
Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance
Committee. Standards and guidelines for the interpretation of sequence variants:
a joint consensus recommendation of the American College of Medical Genetics
and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:
405–524.
12. Liberati A, Altman DG, Tetzlaff J, Mulrow C. The PRISMA statement for
reporting systematic reviews and meta-analyses of studies that evaluate health care
interventions: explanation and elaboration. Plos Med 2009; 6: e1000100.
13. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D,
Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in
epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies
in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–2012.
14. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG,
Moher D, Rennie D, de Vet HC; Standards for Reporting of Diagnostic Accuracy.
Towards complete and accurate reporting of studies of diagnostic accuracy: the
STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem
2003; 49: 1–6.
15. Jansen FA, Blumenfeld YJ, Fisher A, Cobben JM, Odibo AO, Borrell A, Haak
MC. Array comparative genomic hybridization and fetal congenital heart defects; a
systematic review and meta-analysis. Ultrasound Obstet Gynecol 2015; 45: 27–35.
16. Petrovski S, Aggarwal V, Giordano JL, Stosic M, Wou K, Bier L, Spiegel E,
Brennan K, Stong N, Jobanputra V, Ren Z, Zhu X, Mebane C, Nahum O, Wang Q,
Kamalakaran S, Malone C, Anyane-Yeboa K, Miller R, Levy B, Goldstein DB,
Wapner RJ. Whole-exome sequencing in the evaluation of fetal structural anomalies:
a prospective cohort study. Lancet 2019; 393: 758–767.
17. Zhou X, Zhou J, Wei X, Yang Y, Guo M, Deng L, Wang J, Sun L. Whole-exome
sequencing for prenatal diagnosis of fetuses with recurrent nonimmune hydrops
fetalis (NIHF). Prenat Diagn 2020; 40: 3–21.
18. Boissel S, Fallet-Bianco C, Chitayat D, Kremer V, Nassif C, Rypens F, Delrue MA,
Dal Soglio D, Oligny LL, Patey N, Flori E, Cloutier M, Dyment D, Campeau P,
Karalis A, Nizard S, Fraser WD, Audibert F, Lemyre E, Rouleau GA, Hamdan FF,
Kibar Z, Michaud JL. Genomic study of severe fetal anomalies and discovery of
GREB1L mutations in renal agenesis. Genet Med 2018; 20: 745–753.
19. Deng Q, Fu F, Yu Q, Li R, Li F, Wang D, Lei T, Yang X, Liao C. Nonimmune
hydrops fetalis: genetic analysis and clinical outcome. Prenat Diagn 2020; 40:
803–812.
20. Jelin AC, Sobreira N, Wohler E, Solomon B, Sparks T, Sagaser KG, Forster KR,
Miller J, Witmer PD, Hamosh A, Valle D, Blakemore K. The utility of exome
sequencing for fetal pleural effusions. Prenat Diagn 2020; 40: 590–595.
21. Normand EA, Braxton A, Nassef S, Ward PA, Vetrini F, He W, Patel V, Qu C,
Westerfield LE, Stover S, Dharmadhikari AV, Muzny DM, Gibbs RA, Dai H, Meng L,
Wang X, Xiao R, Liu P, Bi W, Xia F, Walkiewicz M, Van den Veyver IB, Eng CM,
Yang Y. Clinical exome sequencing for fetuses with ultrasound abnormalities and a
suspected Mendelian disorder. Genome Med 2018; 10: 74.
22. Vora NL, Powell B, Brandt A, Strande N, Hardisty E, Gilmore K, Foreman AKM,
Wilhelmsen K, Bizon C, Reilly J, Owen P, Powell CM, Skinner D, Rini C,
Lyerly AD, Boggess KA, Weck K, Berg JS, Evans JP. Prenatal exome sequencing
in anomalous fetuses: new opportunities and challenges. Genet Med 2017; 19:
1207–1216.
23. Stals KL, Wakeling M, Baptista J, Caswell R, Parrish A, Rankin J, Tysoe C,
Jones G, Gunning AC, Lango Allen H, Bradley L, Brady AF, Carley H, Carmichael J,
Castle B, Cilliers D, Cox H, Deshpande C, Dixit A, Eason J, Elmslie F, Fry AE,
Fryer A, Holder M, Homfray T, Kivuva E, McKay V, Newbury-Ecob R, Parker M,
Savarirayan R, Searle C, Shannon N, Shears D, Smithson S, Thomas E, Turnpenny
PD, Varghese V, Vasudevan P, Wakeling E, Baple EL, Ellard S. Diagnosis of lethal or
prenatal-onset autosomal recessive disorders by parental exome sequencing. Prenat
Diagn 2018; 38: 33–43.
24. Westphal DS, Leszinksi GS, Rieger-Fackeldey E, Graf E, Weirich G, Meitinger T,
Ostermayer E, Oberhoffeer R, Wagner M. Lessons from exome sequencing in
prenatally diagnosed heart defects: A basis for prenatal testing. Clin Genet 2019; 95:
582–589.
25. Yates CL, Monaghan KG, Copenheaver D, Retterer K, Scuffins J, Kucera CR,
Friedman B, Richard G, Juusola J. Whole-exome sequencing on deceased fetuses
with ultrasound anomalies: expanding our knowledge of genetic disease during fetal
development. Genet Med 2017; 19: 1171–1178.
26. Becher N, Andreasen L, Sandager P, Lou S, Petersen OB, Christensen R, Vogel I.
Implementation of exome sequencing in fetal diagnostics-Data and experiences from
a tertiary center in Denmark. Acta Obstet Gynecol Scand 2020; 99: 783–790.
27. Deden C, Neveling K, Zafeiropopoulou D, Gilissen C, Fundt R, Rinne T, de
Leeuw N, Faas B, Gardeitchik T, Sallevelt SCEH, Paulussen A, Stevens SJC, Sikkel E,
Elting MW, van Maarle MC, Diderich KEM, Corsten-Janssen N, Lichtenbelt KD,
Lachmeijer G, Vissers LELM, Yntema HG, Nelen M, Feenstra I, van Zelst-Stams
WAG. Rapid whole exome sequencing in pregnancies to identify the underlying
genetic cause in fetuses with congenital anomalies detected by ultrasound imaging.
Prenat Diagn 2020; 40: 972–983.
28. Greenbaum L, Pode-Shakked B, Eisenberg-Barzilai S, Dicastro-Keidar M, Bar-Ziv A,
Goldstein N, Reznik-Wolf H, Poran H, Rigbi A, Barel O, Bertoli-Avella AM, Bauer P,
Regev M, Raas-Rothschild A, Pras E, Berkenstadt M. Evaluation of Diagnostic Yield
in Fetal Whole-Exome Sequencing: A Report on 45 Consecutive Families. Front
Genet 2019; 10: 425.
29. Sparks TN, Thao K, Lianoglou BR, Boe NM, Bruce KG, Datkhaeva I, Field
NT, Fratto VM, Jolley J, Laurent LC, Mardy AH, Murphy AM, Ngan E,
Rangwala N, Rottkamp CAM, Wilson L, Wu E, Uy CC, Lopez PV, Norton
ME, University of California Fetal–Maternal Consortium (UCfC). Nonimmune
hydrops fetalis: identifying the underlying genetic etiology. Genet Med 2019; 21:
1339–1344.
30. Westerfield LE, Stover SR, Mathur VS, Nassef SA, Carter TG, Yang Y, Eng
CM, Van den Veyver IB. Reproductive genetic counseling challenges associated
with diagnostic exome sequencing in a large academic private reproductive genetic
counseling practice. Prenat Diagn 2015; 35: 1022–1029.
© 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2021; 58: 509–518.
on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
518 Mone et al.
31. Yang YS, Ma GC, Shih JC, Chen CP, Chou CH, Yeh KT, Kuo SJ, Chen TH, Hwu
WL, Lee TH, Chen M. Experimental treatment of bilateral fetal chylothorax using
in-utero pleurodesis. Ultrasound Obstet Gynecol 2012; 39: 56–62.
32. Corsten-Janssen N, Bouman K, Diphoorn JCD, Scheper AJ, Kinds R, El Mecky,
Breet H, Verheij JBGM, Suijkerbuijk R, Duin LK, Manten GTR, van Langen IM,
Sijmons RH, Sikkema-Raddatz B, Westers H, van Diemen CC. A prospective study
on rapid exome sequencing as a diagnostic test for multiple congenital anomalies on
fetal ultrasound. Prenat Diagn 2020; 40: 1300–1309.
33. Croonen EA, Nillesen WM, Stuurman KE, Oudesluijs G, van de Laar IMBM,
Martens L, Ockeloen C, Mathijssen IB, Schepens M, Ruiterkamp-Versteeg M,
Scheffer H, Faas BHW, van der Burgt I, Yntema HG. Prenatal diagnostic testing
of the Noonan syndrome genes in fetuses with abnormal ultrasound findings. Eur
J Hum Genet 2013; 21: 936–942.
34. Mone F, Doyle S, Hamilton S, Allen S, Williams D, Kilby MD. VP33.06: Non-immune
hydrops fetalis and diagnostic yield with prenatal-exome sequencing: a case series.
Ultrasound Obstet Gynecol 2020; 56: 195.
35. Pehlivan D, Bayram Y, Gunes N, Akdemir ZC, Shukla A, Bierhals T, Tabakci B,
Sahin Y, Gezdirici A, Fatih JM, Gulec EY, Yesil G, Punetha J, Ocak Z, Grochowski
CM, Karaca E, Albayrak HM, Radhakrishnan P, Erdem HB, Sahin I, Yildirim T,
Bayhan IA, Bursali A, Muhsin Elmas M, Yuksel Z, Ozdemir O, Silan F, Yildiz O,
Yesilbas O, Isikay S, Balta B, Gu S, Jhangiani SN, Doddapaneni H, Hu J, Muzny
DM, Baylor-Hopkins Center for Mendelian Genomics; Boerwinkle E, Gibbs RA,
Tsiakas K, Hempel M, Girisha KM, Gul D, Posey JE, Elcioglu NH, Tuysuz B, Lupski
JR. The Genomics of Arthrogryposis, a Complex Trait: Candidate Genes and Further
Evidence for Oligogenic Inheritance. Am J Hum Genet 2019; 105: 132–150.
36. National Genomic Test Directory. NHS England 2020/2021. https://www.england
.nhs.uk/publication/national-genomic-test-directories/
37. Stuurman KE, Joosten M, van der Burgt I, Elting M, Yntema HG, Meijers-Heijboer H,
Rinne T. Prenatal ultrasound findings of rasopathies in a cohort of 424 fetuses: update
on genetic testing in the NGS era. J Med Genet 2019; 56: 654–661.
38. Sileo FG, Kulkarni A, Branescu I, Homfray T, Dempsey E, Mansour S, B
Thilaganathan B, Bhide A, Khalil A. Non-immune fetal hydrops: etiology and
outcome according to gestational age at diagnosis. Ultrasound Obstet Gynecol
2020; 56: 416–421.
39. Mone F, McMullan DJ, Williams D, Chitty LS, Maher ER, Kilby MD; Fetal Genomics
Steering Group of the British Society for Genetic Medicine; the Royal College of
Obstetricians and Gynaecologists. Evidence to Support the Clinical Utility of Prenatal
Exome Sequencing in Evaluation of the Fetus with Congenital Malformations.
Scientific Impact Paper No. 64. BJOG 2021; 28: e39–50.
40. NHS England. Rapid Exome Sequencing Service for Fetal Anomalies Testing.
2021. https://www.england.nhs.uk/wp-content/uploads/2021/07/B0179_Guidance-
rapid-exome-sequencing-service-for-fetal-anomalies_July21.pdf
41. Dempsey E. ISRCTN22076461. A study to improve our understanding of the genetic
causes of swelling in babies before birth. https://doi.org/10.1186/ISRCTN22076461.
42. Achiron R, Heggesh J, Grisaru D, Goldman B, Lipitz S, Yagel S, Frydman M.
Noonan syndrome: a cryptic condition in early gestation. Am J Med Genet 2000;
92: 159–165.
43. Yang X, Huang LY, Pan M, Xu L, Zhen L, Han J, Li D. Exome sequencing improves
genetic diagnosis of fetal increased nuchal translucency. Prenat Diagn 2020; 40:
1426–1431.
44. Mellis R, Eberhardt RY, Hamilton SJ, PAGE Consortium, McMullan DJ, Kilby MD,
Maher ER, Hurles ME, Giordano JL, Aggarwal V, Goldstein DB, Wapner RJ, Chitty
LS. Fetal exome sequencing for isolated increased nuchal translucency: Should we be
doing it? BJOG 2021. DOI: 10.1111/1471-0528.16869.
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article:
Table S1 Documented diagnostic (Class-IV or -V) variants in studies reporting on the incremental yield of
exome sequencing over chromosomal microarray analysis or karyotyping in fetuses with prenatally detected
non-immune hydrops fetalis
Table S2 Documented variants of uncertain significance (Class III) in studies reporting on the incremental yield
of exome sequencing over chromosomal microarray analysis or karyotyping in fetuses with prenatally detected
non-immune hydrops fetalis
Figure S1 Funnel plots for studies reporting on the incremental yield of exome sequencing over chromosomal
microarray analysis or karyotyping in fetuses with prenatally detected non-immune hydrops fetalis (NIHF),
overall (a) and in those with isolated NIHF (b) or NIHF with an additional fetal structural anomaly (c).
Figure S2 Forest plots showing incremental yield of exome sequencing over chromosomal microarray analysis
or karyotyping in fetuses with prenatally detected non-immune hydrops fetalis (NIHF), according to whether
two (a) or three or more (b) body cavities were affected.
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